Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Continuing carfilzomib therapy beyond its known long-term safety limits may provide additional clinical benefit to patients with relapsed multiple myeloma (MM), according to a study published the Journal of Hematology and Oncology.

Results of the ASPIRE trial demonstrated that carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and complete response (CR) rates compared with lenalidomide plus dexamethasone (Rd) alone among patients with relapsed MM. However, carfilzomib was discontinued after 18 treatment cycles due to a lack of long-term safety data and patients continued on Rd alone, leaving the benefit/risk profile of KRd to progression unknown.

Source- https://www.oncologynurseadvisor.com/multiple-myeloma/long-term-carfilzomib-safe-effective-in-relapsed-mm/article/756682/

Leave a Reply

Your email address will not be published. Required fields are marked *